龙迅股份（688486） 证券研究报告·公司深度研究·半导体 专注高速混合信号芯片，25 年把握 AR/VR+ 智驾双重机遇 [Table_Tag] [Table_Summary] 投资要点 ◼ 行业崛起之星，致力于高速混合信号芯片领域。公司专注于高速信号与 视频处理芯片研发生产，产品涵盖模拟和数字电路功能，广泛应用于消 费电子、VR/AR、安防监控、5G 通讯、汽车电子、工业控制和医疗等 领域。公司拥有 140 多款芯片，具备高集成度、高性能、低功耗优势， 与高通、英特尔、三星、安霸等知名企业紧密合作，具备较强国际竞争 力。 ◼ 车载、AR/VR、PC 等多领域发展，成长空间广阔。 （1）车载：公司在车载显示领域深入布局。在智能座舱 SoC 方面，公 司部分高清视频桥接芯片凭借兼容性和稳定性优势已导入车载抬头显 示和信息娱乐系统，其中 9 款芯片通过 AEC-Q100 认证。在车载 SerDes 方面，针对汽车市场对于视频长距离传输和超高清视频显示需求开发的 车载 SerDes 芯片组进入全面市场推广。 （2）AR/VR：国内外 AR/VR 市场前景广阔，公司加速布局。目前，公 司研发的 4K/8K 超高清 ...

分析师及联系人 丨证券研究报告丨 联合研究丨公司点评丨致欧科技（301376.SZ） [Table_Title] 致欧科技 2024 A&2025Q1 点评：品牌力及 经营质量提升，短期扰动不改中长期价值 报告要点 [Table_Summary] 公司 2024 年实现营收/归母净利润/扣非净利润 81.24/3.34/3.09 亿元，同比+34%/-19%/-29%； 其中2024Q4 分别对应同比+24%/-56%/-58%；2025Q1 分别对应同比+14%/+10%/+25%。2024 年至 2025Q1 美线表现更佳，新渠道增势出色。公司内生优化进展显著，增长质量持续提升； 同时积极布局东南亚供应链应对关税影响。持续看好公司作为家居跨境出海先锋，持续强化竞 争力。 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_Author] SAC：S0490516060001 SAC：S0490514080004 SAC：S0490520070002 SAC：S0490524110002 SAC：S0490524080008 SFC：BUV463 S ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [2]. Core Views - The company is transitioning from a motorcycle business to an "AI + Vehicle" model, with a focus on smart driving and Robotaxi services, supported by strong capital and management backgrounds [8][14]. - The company is expected to achieve significant revenue growth, with projected revenues of 89.66 billion, 102.92 billion, and 121.76 billion yuan for 2025, 2026, and 2027 respectively, alongside net profits of 0.84 billion, 1.53 billion, and 2.51 billion yuan [8][7]. Summary by Sections Company Overview - The company has evolved through four stages: starting with motorcycles, exploring new energy, undergoing bankruptcy restructuring, and now embracing the "AI + Vehicle" transformation [14]. - Its core business includes terminal operations (motorcycles and vehicles) and technology operations (smart driving solutions) [14][19]. Market Performance - The company has seen a significant recovery in its automotive business, with a 117% year-on-year increase in new energy vehicle sales in Q1 2025 [23][24]. - The motorcycle business has maintained a stable cash flow, with a gross margin of 12.1% in 2023, showing an upward trend [26][29]. Smart Driving and Technology - The report highlights the importance of smart driving technology, which is categorized into Advanced Driver Assistance Systems (ADAS) and higher-level autonomous driving [39][41]. - The domestic policy environment is supportive of the autonomous driving industry, with multiple regulations and incentives in place to promote development [43][44]. Financial Projections - Revenue forecasts indicate a recovery trajectory, with expected revenues of 89.66 billion yuan in 2025, reflecting a growth rate of 27.45% [7][8]. - The company's net profit is projected to grow significantly, with a forecasted increase of 110.17% in 2025 [7]. Competitive Landscape - The company is positioned to leverage partnerships with major players like Geely and AI firms to enhance its technology capabilities and market reach [8][19]. - The report notes that the company’s gross margin is currently below the average of comparable companies, but improvements are anticipated as AI-related businesses develop [32].

[Table_Title] 研究报告 Research Report 18 May 2025 泛亚微透 Pan Asian Microvent Tech (Jiangsu) (688386 CH) ePTFE 材料领先企业，加速推进国产替代 The leading enterprise in ePTFE, accelerating the promotion of domestic substitution 孙小涵 Xiaohan Sun xh.sun@htisec.com [Table_yemei1] 热点速评 Flash Analysis [Table_yejiao1] 本研究报告由海通国际分销，海通国际是由海通国际研究有限公司，海通证券印度私人有限公司，海通国际株式会社和海通国 际证券集团其他各成员单位的证券研究团队所组成的全球品牌，海通国际证券集团各成员分别在其许可的司法管辖区内从事证 券活动。关于海通国际的分析师证明，重要披露声明和免责声明，请参阅附录。(Please see appendix for English translation of the disclaimer) 公司是中国 ePTF ...

证券研究报告·A 股公司简评 黑色家电 电视&显示器高增， Q1 收入业绩稳健增长 核心观点 公司是全球 TV 及 IFPD 代工龙头，2024 年 IFPD 代工受行业需 求下滑影响，收入规模及占比下滑，智能电视代工以及显示器等 新兴品类贡献收入增长，受面板成本上涨及产品结构调整影响， 利润率短期下滑。公司大力发展创新类显示产品，推动自有品牌 出海，电竞显示器、移动智慧屏、AI 学习机、智能美妆镜等系列 创新产品不断涌现，预计 2025 年收入利润重返上升趋势。 事件 2025 年 3 月 31 日，康冠科技发布 2024 年年度报告。2025 年 4 月 29 日，康冠科技发布 2025 年一季报。 公司 2024 年实现营收 155.87 亿元（YOY+15.92%），归母净利 润 8.33 亿元（YOY-35.02%），净利率为 5.35%（YOY-4.19pct）； 其中 Q4 实现营收 41.95 亿元（YOY-14.12%），归母净利润 2.75 亿元（YOY-34.12%），净利率为 6.56%（YOY-1.99pct）。2025Q1 实现营业收入 31.42 亿元（YOY+10.82%），归 ...

丨证券研究报告丨 公司研究丨点评报告丨光峰科技（688007.SH） [Table_Title] 营收稳健增长，车载业务进入快速放量阶段 报告要点 [Table_Summary] 2024 年公司实现营业收入 24.19 亿元，同比增长 9.27%，实现归母净利润 2795 万元，同比下 滑 72.91%，实现扣非归母净利润 3213 万元，同比下滑 22.88%；其中，2024Q4 公司实现营 业收入 6.99 亿元，同比增长 24.21%，实现归母净利润-1499 万元，同比减亏 1038 万元，实 现扣非归母净利润-747 万元，同比减亏 2736 万元。此外，2025Q1 公司实现营业收入 4.61 亿 元，同比增长 3.67%，实现归母净利润-2136 万元，同比下滑 147.95%，实现扣非归母净利润 -2397 万元，同比转亏。 分析师及联系人 [Table_Author] 陈亮 SAC：S0490517070017 SFC：BUW408 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 光峰科技（688007.SH） cjzqdt11111 [Ta ...

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 21 yuan [2][8]. Core Views - The medical device sector faced temporary pressure, while the pharmaceutical equipment segment showed steady growth. The company reported a slight increase in total revenue for 2024, reaching 10.021 billion yuan, and a net profit of 692 million yuan, reflecting a year-on-year growth of 5.75% [2][4]. - The company plans to distribute a cash dividend of 0.25 yuan per share (before tax) to all shareholders [2]. Financial Performance Summary - For 2024, the company achieved total revenue of 10,021 million yuan, with a year-on-year growth of 0.1%. The net profit attributable to the parent company was 692 million yuan, up 5.8% year-on-year [4][8]. - In Q4 2024, the company reported a revenue of 2,597 million yuan, a decrease of 3.63%, and a net profit of 75 million yuan, down 0.97% [2][4]. - For Q1 2025, the revenue was 2,308 million yuan, down 8.74%, and the net profit was 160 million yuan, a decrease of 23.97% [2][4]. Segment Performance - The medical device segment generated revenue of 3,735 million yuan in 2024, down 10.37%. The pharmaceutical equipment segment saw revenue of 2,171 million yuan, an increase of 12.90%. The medical trade segment reported 3,125 million yuan, up 8.04%, while medical services revenue was 834 million yuan, down 9.51% [2][8]. - The company is actively expanding its overseas market presence, achieving a 16.51% increase in overseas revenue to 281 million yuan in 2024 [2][8]. Profitability and Margin Analysis - The overall gross margin for 2024 was 26.06%, slightly down by 1.31 percentage points. The net profit margin improved to 6.90%, an increase of 0.14 percentage points, due to a decrease in sales and management expense ratios [2][8]. - In Q1 2025, the gross margin decreased to 23.79%, and the net profit margin fell to 6.99%, reflecting changes in product structure and increased expense ratios [2][8]. Earnings Forecast and Valuation - The company is expected to achieve net profits of 800 million yuan, 930 million yuan, and 1,030 million yuan for 2025, 2026, and 2027, respectively, with year-on-year growth rates of 15.4%, 16.2%, and 10.7% [2][4]. - The estimated earnings per share (EPS) for the next three years are projected to be 1.32 yuan, 1.53 yuan, and 1.69 yuan, with corresponding price-to-earnings (PE) ratios of 12, 10, and 9 [4][8].

证券研究报告·A 股公司简评 其他电源设备Ⅱ 2024 年年报及 2025 年一季报点评：高额现金 事件 公司2024年实现营收/归母净利润/扣非后归母净利润 91.1/7.0/3.9 亿元，同比-13%/-5%/-24%； 其 中 2024Q4 实 现 营 收 / 归母净利润 / 扣 非 后 归 母 净 利 润 18.8/2.2/1.6 亿元，同比 -33%/-1%/+511% ，环比 +28%/+166%/+521%。 2025Q1 实现营收/归母净利润/扣非后归母净利润 19.7/1.3/1. 2 亿 元，同比-32%/-31%/-35%，环比+4%/-42%/-26%。 简评 1、 设备端： 1）2024 年收入 17.42 亿元，同比+20.18%，系高端环保锅 炉市场开发+燃机余热炉收入增长较快，预计环保/余热锅炉 毛利率分别 6.8%，15.7%，同比下滑 5-7pct，主要系市场竞 争激烈，价格端承压。 2）在手订单：公司锅炉装备在手订单总量 30.44 亿元，同 比+43%，其中环保锅炉装备在手订单 11.1 亿元，传统节 能高效锅炉在手订单 15.29 亿元，另有设备更新改造及备件 等订单 ...

Investment Rating - The investment rating for the company is "Buy" [6][12] Core Views - The company is a leading player in the in vitro diagnostics sector, with a diversified business layout that continues to grow [6][12] - In 2024, the company is expected to achieve revenue of 4.471 billion yuan, representing a growth of 0.62%, while the net profit attributable to the parent company is projected to be 1.194 billion yuan, a decrease of 1.89% [6][12] - The company's main business operations are stable, with notable performance in molecular diagnostics and overseas markets [2][6] Financial Performance Summary - For 2024, the company's revenue is projected to be 44.71 billion yuan, with a slight increase of 0.62%, and the net profit is expected to be 11.94 billion yuan, down by 1.89% [2][4] - In Q1 2025, the company reported revenue of 9.96 billion yuan, a decrease of 8.56%, and a net profit of 2.70 billion yuan, down by 16.76% [2][4] - The revenue from the reagent segment in 2024 is expected to be 37.97 billion yuan, with immunodiagnostic products contributing 25.56 billion yuan, an increase of 2.91% [2][4] - The company achieved domestic revenue of 41.05 billion yuan in 2024, a decrease of 1.30%, while overseas revenue reached 2.84 billion yuan, an increase of 36.25% [2][4] Research and Development Summary - The company increased its R&D investment to 7.32 billion yuan in 2024, a year-on-year increase of 11.55% [2][4] - In 2024, the company registered 144 new reagent product certificates, covering advanced technology fields such as chemiluminescence and molecular diagnostics [2][4] - The launch of the AutoChem B2000/B800 series of fully automated biochemical analyzers marks a significant development in the biochemical product field [2][4] Profitability and Financial Ratios - The company's gross margin for 2024 is projected to be 65.41%, reflecting a stable performance [2][4] - The sales, management, and R&D expense ratios for 2024 are expected to be 17.17%, 4.72%, and 16.37%, respectively [2][4] - The projected EPS for 2025, 2026, and 2027 are 2.24 yuan, 2.66 yuan, and 3.08 yuan, respectively [2][4]

Investment Rating - The report maintains a "Buy" rating for the company, with expected net profits of 8.1 billion, 10.0 billion, and 12.1 billion for 2025, 2026, and 2027 respectively, corresponding to P/E ratios of 28, 22, and 18 [14]. Core Views - The company is expected to ship over 430,000 tons of negative electrode materials in 2024, representing a year-on-year increase of 19%, slightly below industry growth due to a slowdown in overseas demand [11]. - The company has established a solid-state electrolyte production line with an annual capacity exceeding 100 tons, serving clients in the power and 3C sectors, and has already achieved shipments [16]. - The company’s revenue for 2024 is projected at 14.24 billion, with a net profit of 930 million, reflecting a year-on-year decline of 43% [2]. Summary by Sections Negative Electrode - The company is expected to achieve a gross profit of approximately 2,800 yuan per ton in the negative electrode segment for 2024, with projected profits of 2,900 yuan and 1,700 yuan per ton for Q4 2024 and Q1 2025 respectively [11]. - The decline in Q1 profitability is attributed to foreign exchange losses estimated at 60-70 million yuan, competitive pressure from overseas clients, and rising petroleum coke prices affecting performance [11]. Positive Electrode - The company has a production capacity of 63,000 tons per year for positive electrode materials, with a new high-nickel positive electrode project in Changzhou expected to be completed in 2024 [4]. Financial Performance - The company reported revenues of 39.7 million and a net profit of 2.6 million for Q4 2024, showing a year-on-year decline of 17% and 10% respectively, but a quarter-on-quarter increase of 23% and 45% [2]. - For Q1 2025, the company achieved revenues of 33.9 million, with a net profit of 1.8 million, reflecting a year-on-year decline of 4% and 19% respectively [2]. Future Outlook - The company is expanding its overseas production capacity, with an integrated project in Indonesia for 80,000 tons of negative electrode materials gradually coming online, which is expected to enhance shipment volumes and global market share [11].